This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Like Dr Fournier and colleagues, we are uncertain about the possibility of class-specific differences in clinical outcomes (such as stroke or myocardial infarction) among antihypertensive drugs. Although debate continues about their relative efficacies, thiazide diuretics, -blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and long-acting dihydropyridine calcium channel blockers have been shown to reduce the risk of stroke. However, given the results of the recently published ALLHAT trial¹ and the relative costs of the various agents, we believe that thiazide diuretics remain the agents of first choice in hypertensive patients for the primary prevention of cardiovascular and cerebrovascular disease. Furthermore, a meta-regression of 27 antihypertensive drug trials found that the reductions in stroke (as well as other cardiovascular end points) from antihypertensive therapy observed in these trials could be explained by the achieved differences in SBP.² Of note, this meta-regression included the CAPPP trial that Fournier et al mention.

. . . [Full Text of this Article]

Sharon E. Straus, MD, FRCPC
Department of Medicine
University of Toronto
Toronto, Ontario

Finlay A. McAlister, MD, FRCPC; Sumit R. Majumdar, MD, FRCPC
Division of General Internal Medicine
University of Alberta
Edmonton

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Reducing the Risk of Stroke
Albert Fournier, Roxana Oprisiu, Michel Andrejak, Jean Michel Achard, and Leonardo Fernandez
JAMA. 2003;289(15):1927-1928.
EXTRACT | FULL TEXT  

Reducing the Risk of Stroke
Kamakshi Lakshminarayan and David C. Anderson
JAMA. 2003;289(15):1928.
EXTRACT | FULL TEXT  

Reducing the Risk of Stroke
Howard S. Kirshner
JAMA. 2003;289(15):1928.
EXTRACT | FULL TEXT  

Reducing the Risk of Stroke
James M. Gebel and Louis R. Caplan
JAMA. 2003;289(15):1928.
EXTRACT | FULL TEXT  

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2002;288(23):2981-2997.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

From The Cover: Identification of a high-affinity binding site involved in the transport of endocannabinoids
Moore et al.
Proc. Natl. Acad. Sci. USA 2005;102:17852-17857.
ABSTRACT | FULL TEXT  

{Delta}-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response
McKallip et al.
J. Immunol. 2005;174:3281-3289.
ABSTRACT | FULL TEXT  

The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2
Newton et al.
J. Leukoc. Biol. 2004;76:854-861.
ABSTRACT | FULL TEXT